Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine

Experimental Neurology

Volumn 146, Issue 2, 1997, Pages 526-535

  Matsuura, Kouji ^a   Makino, Hirofumi ^a   Ogawa, Norio ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; ENZYME ACTIVITY; MALE; MICROGLIA; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STRIATE CORTEX; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA;

EID: 0031214457     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6575     Document Type: Article

References (55)

1. 1. Adams, J. C. 1981. Heavy metal intensification of DAB-based HRP reaction product. J. Histochem. Cytochem. 29: 775.
2. 2. Altar, C. A., C. B. Boylan, M. Fritsche, C. Jackson, C. Hyman, and R. M. Lindsay. 1994. The neurotrophins NT-4/5 and BDNF augment serotonin, dopamine, and GABAergic systems during behaviorally effective infusions to the substantia nigra. Exp. Neurol. 130: 31-40.
3. 3. Altar, C. A., C. B. Boylan, M. Fritsche, B. E. Jones, C. Jackson, S. J. Wiegand, R. M. Lindsay, and C. Hyman. 1994. Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions. J. Neurochem. 63: 1021-1032.
4. 4. Altar, C. A., C. B. Boylan, C. Jackson, S. Hershenson, J. Miller, S. Wiegand, R. M. Lindsay, and C. Hyman. 1992. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc. Natl. Acad. Sci. USA 89: 11347-11351.
5. 5. Altar, C. A., L. B. Jakeman, I. N. Acworth, R. Soriano, and M. D. Djordjevic. 1992. Regionally restricted loss and partial recovery of nigrostriatal dopamine input following intrastriatal 6-hydroxydopamine. Neurodegeneration 1: 123-133.
6. 6. Banati, R. B., J. Gehrmann, P. Schubert, and G. W. Kreutzberg. 1993. Cytotoxicity of microglia. Glia 7: 111-118.
7. 7. Ben, S. D., G. Eshel, J. P. Finberg, and M. B. Youdim. 1991. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56: 1441-1444.
8. 8. Berden, J. H. M., A. J. Hottsuma, J. L. Merx, and A. Keyser. 1985. Severe central-nervous-system toxicity associated with cyclosporin. Lancet 1: 219-220.
9. 9. Berger, K., S. Przedborski, and J. L. Cadet. 1991. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res. Bull. 26: 301-307.
10. 10. Bowenkamp, K. E., A. F. Hoffman, G. A. Gerhardt, M. A. Henry, P. T. Biddle, B. J. Hoffer, and A. C. Granholm. 1995. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J. Comp. Neurol. 355: 479-489.
11. 11. Cadet, J. L., M. Katz, L. V. Jackson, and S. Fahn. 1989. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence. Brain Res. 476: 10-15.
12. 12. Chadi, G., A. Moller, L. Rosen, A. M. Janson, L. A. Agnati, M. Goldstein, S. O. Ogren, R. F. Pettersson, and K. Fuxe. 1993. Protective actions of human recombinant basic fibroblast growth factor on MPTP-lesioned nigrostriatal dopamine neurons after intraventricular infusion. Exp. Brain Res. 97: 145-158.
13. 13. Espino, A., B. Cutillas, A. Tortosa, I. Ferrer, R. Bartrons, and S. Ambrosio. 1995. Chronic effects of single intrastriatal injections of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium studied by microdialysis in freely moving rats. Brain Res. 695: 151-157.
14. 14. Goto, S., Y. Matsykado, Y. Mihara, N. Inoue, and E. Miyamoto. 1986. The distribution of calcineurin in rat brain by light and electron microscopic immunohistochemistry and enzyme-immunoassay. Brain Res. 397: 161-172.
15. 15. Group, T. P. S. 1989. Effect of deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 321: 1364-1371.
16. 16. Group, T. P. S. 1993. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328: 176-183.
17. 17. Hadjiconstantinou, M., J. G. Fitkin, A. Dalia, and N. H. Neff. 1991. Epidermal growth factor enhances striatal dopaminergic parameters in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. J. Neurochem. 57: 479-482.
18. 18. Hadjiconstantinou, M., A. P. Mariani, and N. H. Neff. 1989. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: An immunohistochemical study. Brain Res. 484: 297-303.
19. 19. Hagihara, M., K. Fujishiro, A. Takahashi, M. Naoi, and T. Nagatsu. 1989. Cyclosporin A, an immune suppressor, enhanced neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Neurochem. Int. 15: 249-254.
20. 20. Ichitani, Y., H. Okamura, D. Nakahara, I. Nagatsu, and Y. Ibata. 1994. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: Evidence for cell death in the substantia nigra. Exp. Neurol. 130: 269-278.
21. 21. Jones, B. E., C. B. Boylan, M. Fritsche, M. Juhasz, C. Jackson, S. J. Wiegand, C. Hyman, R. M. Lindsay, and C. A. Altar. 1996. A continuous striatal infusion of 6-hydroxydopamine produces a terminal axotomy and delayed behavioral effects. Brain Res. 709: 275-284.
22. 22. Lad, R. P., M. A. Smith, and D. C. Hilt. 1991. Molecular cloning and regional distribution of rat brain cyclophilin. Mol. Brain Res. 9: 239-244.
23. 23. Lange, K. W., and P. Riederer. 1994. Glutamatergic drugs in Parkinson's disease. Life Sci. 55: 2067-2075.
24. 24. Lindsay, R. M., C. A. Altar, J. M. Cedarbaum, C. Hyman, and S. J. Wiegand. 1993. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Exp. Neurol. 124: 103-118.
25. 25. Martin-Iverson, M. T., K. G. Todd, and C. A. Altar. 1994. Brain-derived neurotrophic factor and neurotrophin-3 activates striatal dopamine and serotonin metabolism and related behaviors: Interactions with amphetamine. J. Neurosci. 14: 1262-1270.
26. 26. Marty, S., I. Dusart, and M. Peschanski. 1991. Glial changes following an excitotoxic lesion in the CNS. I. Microglia/macrophages. Neuroscience 45: 529-539.
27. 27. Matsuura, K., H. Kabuto, H. Makino, and N. Ogawa. 1996. Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain. Brain Res. 733: 101-104.
28. 28. McGeer, P. L., S. Itagaki, B. E. Boyes, and E. G. McGeer. 1988. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38: 1285-1291.
29. 29. Ogawa, N. 1994. Levodopa and dopamine agonists in the treatment of Parkinson's disease: Advantages and disadvantages. Eur. Neurol. 3: 20-28.
30. 30. Ogawa, N. 1995. Possible neuroprotective therapy for Parkinson's disease. Acta Med. Okayama 49: 179-185.
31. 31. Ogawa, N., K. Haba, M. Asanuma, and A. Mori. 1991. Long-lasting effect of ceruletide on dyskinesia and monoaminergic neuronal pathways in rats treated with iminodipropionitrile. Brain Res. 556: 271-279.
32. 32. Ogawa, N., K. Tanaka, Y. Kondo, M. Asanuma, K. Mizukawa, and A. Mori. 1993. The preventive effect of cyclosporin A, an immunosuppressant, on theblate onset reduction of muscarinic acetylcholine receptors in gerbil hippocampus after transient forebrain ischemia. Neurosci. Lett. 152: 173-176.
33. 33. Otto, D., and K. Unsicker. 1994. FGF-2 in the MPTP model of Parkinson's disease: effects on astroglial cells. Glia 11:47-56.
34. 34. Pantelatos, A., and F. Fornadi. 1993. Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset. Adv. Neurol. 60: 690-697.
35. 35. Ricaurte, G. A., L. E. DeLanney, I. Irwin, and J. W. Langston. 1987. Older dopminergic neurons do not recover from the effects of MPTP. Neuropharmacology 26: 97-99.
36. 36. Robertson, G. S., and H. A. Robertson. 1989. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. J. Neurosci. 9: 3326-3331.
37. 37. Sauer, H., and W. H. Oertel. 1994. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 59: 401-415.
38. 1 ganglioside-induced recovery of concentrations of dopamine in the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. Neuropharmacology 31: 185-192.
39. 1 ganglioside treatment. Neuroreport 5: 103-104.
40. 40. Schneider, J. S., and L. DiStefano. 1994. Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in a murine model of parkinsonism. Neurology 44: 748-750.
41. 1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice. J. Neurosci. Res. 42: 117-123.
42. 1 ganglioside treatment. Science 256: 843-846.
43. 1 ganglioside treatment of Parkinson's disease: An open pilot study of safety and efficacy. Neurology 45: 1149-1154.
44. 44. Shiga, Y., H. Onodera, Y. Matsuo, and K. Kogure. 1992. Cyclosporin A protects against ischemia-reperfusion injury in the brain. Brain Res. 595: 145-148.
45. 45. Shults, C. W., R. T. Matthews, C. A. Altar, L. R. Hill, and P. J. Langlais. 1994. A single intramesencephalic injection of brain-derived neurotrophic factor induces persistent rotational asymmetry in rats. Exp. Neurol. 125: 183-194.
46. 46. Spina, M. B., S. P. Squinto, J. Miller, R. M. Lindsay and C. Hyman. 1992. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: Involvement of the glutathione system. J. Neurochem. 59: 99-106.
47. 47. Steiner, J. P., T. M. Dawson, M. Fotuhi, C. E. Glatt, A. M. Snowman, N. Cohen, and S. H. Synder. 1992. High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature 358: 584-587.
48. 48. Streit, W. J., and G. W. Kreutzberg. 1987. Lectin binding by resting and reactive microglia. J. Neurocytol. 16: 249-260.
49. 49. Tatton, W. G. 1993. Selegiline can mediate neuronal rescue rather than neuronal protection. Mov. Disord. 8(suppl 1): S20-S30.
50. 50. Tillotson, M. L., and J. G. Wood. 1989. Phosphotyrosine antibodies specifically label ameboid microglia in vitro and ramified microglia in vivo. Glia 2: 412-419.
51. 51. Tomac, A., E. Lindqvist, L. F. Lin, S. O. Ogren, D. Young, B. J. Hoffer, and L. Olson. 1995. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373: 335-339.
52. 52. Venero, J. L., R. M. Romero, M. Revuelta, A. Machado, and J. Cano. 1995. Intrastriatal quinolinic acid injections protect against 6-hydroxydopamine-induced lesions of the dopaminergic nigrostriatal system. Brain Res. 672: 153-158.
53. 53. Wakita, H., H. Tomimoto, I. Akiguchi, and J. Kimura. 1995. Protective effect of cyclosporin A on white matter changes in the rat brain after chronic cerebral hypoperfusion. Stroke 26: 1415-1422.
54. 54. Walaas, S. I., D. W. Aswad, and P. Greengard. 1983. A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine innervated brain regions. Nature 301: 69-71.
55. 55. Wera, S., and J. Neyts. 1994. Calcineurin as a possible new target for treatment of Parkinson's disease. Med. Hypothes. 43: 132-134.